€40.27
1.82%
Xetra, Oct 05, 01:40 pm CEST. Market open.
ISIN
DE0005785802
Symbol
FME
Index

Fresenius Medical Care Target price 2026 - Analyst rating & recommendation

Fresenius Medical Care Classifications & Recommendation

Buy
21%
Hold
38%
Sell
41%

Fresenius Medical Care Price Target

Target Price €42.84
Price €39.55
Potential 8.32%
Number of Estimates 24
24 Analysts have issued a price target Fresenius Medical Care 2027 . The average Fresenius Medical Care target price is €42.84. This is 8.32% higher than the current stock price. The highest price target is €67.20 69.91% , the lowest is €21.94 44.52% .
A rating was issued by 29 analysts: 6 Analysts recommend Fresenius Medical Care to buy, 11 to hold and 12 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Fresenius Medical Care stock has an average upside potential 2027 of 8.32% . Most analysts recommend the Fresenius Medical Care stock at Sale.

Sales and Margin forecast 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion € 19.63 19.61
1.51% 0.07%
EBITDA Margin 16.64% 18.07%
6.95% 8.60%
Net Margin 4.98% 5.59%
79.18% 12.14%

23 Analysts have issued a sales forecast Fresenius Medical Care 2026 . The average Fresenius Medical Care sales estimate is

€19.6b
unlock
. This is
0.96% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€21.0b 7.99%
unlock
, the lowest is
€18.7b 3.54%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 €19.6b 1.51%
2026
€19.6b 0.07%
unlock
2027
€20.3b 3.40%
unlock
2028
€21.1b 3.92%
unlock
2029
€22.4b 6.48%
unlock
2030
€23.5b 4.88%
unlock
2031
€25.0b 6.22%
unlock
2032
€25.9b 3.64%
unlock
2033
€26.8b 3.54%
unlock

19 Analysts have issued an Fresenius Medical Care EBITDA forecast 2026. The average Fresenius Medical Care EBITDA estimate is

€3.5b
unlock
. This is
6.54% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€4.0b 21.39%
unlock
, the lowest is
€3.0b 11.26%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 €3.3b 8.57%
2026
€3.5b 8.51%
unlock
2027
€3.7b 3.24%
unlock
2028
€3.9b 5.22%
unlock
2029
€4.0b 4.70%
unlock
2030
€4.2b 5.16%
unlock
2031
€4.2b 0.21%
unlock
2032
€4.4b 3.77%
unlock
2033
€4.6b 3.65%
unlock

EBITDA Margin

2025 16.64% 6.95%
2026
18.07% 8.60%
unlock
2027
18.04% 0.17%
unlock
2028
18.27% 1.27%
unlock
2029
17.96% 1.70%
unlock
2030
18.01% 0.28%
unlock
2031
16.99% 5.66%
unlock
2032
17.01% 0.12%
unlock
2033
17.03% 0.12%
unlock

22 Fresenius Medical Care Analysts have issued a net profit forecast 2026. The average Fresenius Medical Care net profit estimate is

€1.1b
unlock
. This is
16.91% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€1.3b 34.08%
unlock
, the lowest is
€963m 2.70%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 €978m 81.88%
2026
€1.1b 12.06%
unlock
2027
€1.2b 4.92%
unlock
2028
€1.3b 15.28%
unlock
2029
€1.6b 20.99%
unlock
2030
€1.8b 11.35%
unlock
2031
€2.0b 9.76%
unlock
2032
€2.1b 6.35%
unlock
2033
€2.2b 7.17%
unlock

Net Margin

2025 4.98% 79.18%
2026
5.59% 12.14%
unlock
2027
5.67% 1.43%
unlock
2028
6.29% 10.93%
unlock
2029
7.15% 13.67%
unlock
2030
7.59% 6.15%
unlock
2031
7.84% 3.29%
unlock
2032
8.05% 2.68%
unlock
2033
8.33% 3.48%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share € 3.36 4.12
83.61% 22.62%
P/E 9.60
EV/Sales 1.02

22 Analysts have issued a Fresenius Medical Care forecast for earnings per share. The average Fresenius Medical Care EPS is

€4.12
unlock
. This is
18.05% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
€4.73 35.53%
unlock
, the lowest is
€3.62 3.72%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 €3.36 83.61%
2026
€4.12 22.62%
unlock
2027
€4.32 4.85%
unlock
2028
€4.98 15.28%
unlock
2029
€6.03 21.08%
unlock
2030
€6.71 11.28%
unlock
2031
€7.37 9.84%
unlock
2032
€7.84 6.38%
unlock
2033
€8.40 7.14%
unlock

P/E ratio

Current 11.33 41.87%
2026
9.60 15.29%
unlock
2027
9.15 4.69%
unlock
2028
7.94 13.22%
unlock
2029
6.56 17.38%
unlock
2030
5.89 10.21%
unlock
2031
5.37 8.83%
unlock
2032
5.05 5.96%
unlock
2033
4.71 6.73%
unlock

Based on analysts' sales estimates for 2026, the Fresenius Medical Care stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.03 5.50%
2026
1.02 0.72%
unlock
2027
0.99 3.29%
unlock
2028
0.95 3.77%
unlock
2029
0.89 6.08%
unlock
2030
0.85 4.65%
unlock
2031
0.80 5.86%
unlock
2032
0.77 3.51%
unlock
2033
0.75 3.41%
unlock

P/S ratio

Current 0.54 15.45%
2026
0.54 0.94%
unlock
2027
0.52 3.29%
unlock
2028
0.50 3.77%
unlock
2029
0.47 6.08%
unlock
2030
0.45 4.66%
unlock
2031
0.42 5.87%
unlock
2032
0.41 3.51%
unlock
2033
0.39 3.42%
unlock

Current Fresenius Medical Care Upgrades & Downgrades

Analyst Rating Action Date
BERENBERG
Buy
➜
Buy
Unchanged Sep 21 2026
ODDO BHF
Buy
➜
Buy
Unchanged Sep 04 2026
INTESA SANPAOLO EQUITY RESEARCH
Buy
➜
Buy
Unchanged Aug 31 2026
BNP PARIBAS
Neutral
➜
Underperform
Downgrade Aug 31 2026
METZLER EQUITIES
Hold
➜
Hold
Unchanged Aug 28 2026
LANDESBANK BADEN-WUERTTEMBERG
Buy
➜
Buy
Unchanged Aug 26 2026
TRUIST SECURITIES
Hold
➜
Hold
Unchanged Aug 25 2026
Analyst Rating Date
Unchanged
BERENBERG:
Buy
➜
Buy
Sep 21 2026
Unchanged
ODDO BHF:
Buy
➜
Buy
Sep 04 2026
Unchanged
INTESA SANPAOLO EQUITY RESEARCH:
Buy
➜
Buy
Aug 31 2026
Downgrade
BNP PARIBAS:
Neutral
➜
Underperform
Aug 31 2026
Unchanged
METZLER EQUITIES:
Hold
➜
Hold
Aug 28 2026
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
Aug 26 2026
Unchanged
TRUIST SECURITIES:
Hold
➜
Hold
Aug 25 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today